2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Colonic Neoplasms
4
Congenital Abnormalities
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Somatostatinoma
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Colorectal Neoplasms
2
Carcinoma, Islet Cell
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Interventions
pembrolizumab
7
lenvatinib
3
apatinib
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Carboplatin
3
gallium 68 PSMA-11
2
Specimen Handling
2
Protons
2
Nivolumab
2
Epirubicin
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Trastuzumab
1
Tablets
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Biological Therapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled